@entity7062 in the urological management of the difficult XXXX in spinal cord injury: preliminary report.

@entity1 @entity7062 @entity1494 @entity602 @entity2507 @entity10 @entity2183 @entity2753 @entity130
The purpose of this study is to determine the efficacy of desmopressin ( @entity7062 ), a synthetic analogue of antidiuretic hormone, as an alternative therapy in the management of @entity602 ( @entity602 ) @entity1 with neurogenic @entity1494 unresponsive to conventional therapy. Seven @entity602 @entity1 (three @entity1 and four @entity1 ) were treated with @entity7062 after urodynamic evaluation. Despite treatment with anticholinergic agents, urodynamic evaluation demonstrated uninhibited detrusor contractions exceeding 30 cm @entity2507 pressure at less than 300 ml cystometric capacity in all seven @entity1 . Three @entity1 had been managed with intermittent self-catheterization, but had socially unacceptable short intervals between catheterizations. Two @entity1 with @entity130 were afflicted with significant @entity2183 (> 3 episodes/night). The remaining two @entity1 managed with intermittent self-catheterization were troubled with nocturnal enuresis. The @entity1 received 10 micrograms intranasal @entity7062 once every 24 hours. Prior to @entity7062 administration, the four @entity1 who used @entity7062 nightly experienced a median of four episodes of @entity2183 . After one month of @entity7062 treatment, two @entity1 had only one episode of @entity2183 per night and in the other two @entity1 , nocturnal enuresis was completely eliminated. Three @entity1 used daytime @entity7062 administration at work to avoid frequent catheterization. The median period between bladder catheterizations increased from 2.5 hours before @entity7062 to 6 hours while using @entity7062 . Symptomatic improvement persisted during the follow-up period of 6-20 months (mean = 12). Side effects were infrequent; only one @entity1 complained of transient @entity10 . Neither @entity2753 nor serum electrolyte abnormalities occurred. Our preliminary results suggest that @entity7062 is safe and effective in the symptomatic management of complicated neurogenic @entity1494 in selected @entity602 @entity1 .
